Combination Chemotherapy After Surgery in Treating Patients With High-Risk Stage II or Stage III Colorectal Cancer
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00749450 |
Recruitment Status :
Completed
First Posted : September 9, 2008
Last Update Posted : July 27, 2018
|
Tracking Information | ||||
---|---|---|---|---|
First Submitted Date ICMJE | September 6, 2008 | |||
First Posted Date ICMJE | September 9, 2008 | |||
Last Update Posted Date | July 27, 2018 | |||
Study Start Date ICMJE | March 2008 | |||
Actual Primary Completion Date | November 2017 (Final data collection date for primary outcome measure) | |||
Current Primary Outcome Measures ICMJE |
3-year disease-free survival [ Time Frame: 3 years ] | |||
Original Primary Outcome Measures ICMJE |
3-year disease-free survival | |||
Change History | ||||
Current Secondary Outcome Measures ICMJE |
|
|||
Original Secondary Outcome Measures ICMJE |
|
|||
Current Other Pre-specified Outcome Measures | Not Provided | |||
Original Other Pre-specified Outcome Measures | Not Provided | |||
Descriptive Information | ||||
Brief Title ICMJE | Combination Chemotherapy After Surgery in Treating Patients With High-Risk Stage II or Stage III Colorectal Cancer | |||
Official Title ICMJE | Short Course Oncology Therapy - A Study of Adjuvant Chemotherapy in Colorectal Cancer | |||
Brief Summary | RATIONALE: Drugs used in chemotherapy, such as oxaliplatin, fluorouracil, and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known which combination chemotherapy regimen is more effective in treating patients who have undergone surgery for high-risk colorectal cancer. PURPOSE: This randomized phase III trial is studying chemotherapy given after surgery in treating patients with high-risk stage II or stage III colorectal cancer. |
|||
Detailed Description | OBJECTIVES:
OUTLINE: This is a multicenter study. Patients are stratified according to participating center's recruitment potential. Patients are randomized (within 10 weeks after surgery and before or after receiving 12 weeks of chemotherapy) to 1 of 2 treatment arms. The treatment regimen that a patient receives (Oxaliplatin Modified DeGramont [OxMdG] or XELOX) is determined by the participating center.
The two adjuvant combination chemotherapy regimens are administered as follows:
Patients complete quality-of-life assessments periodically using the EORTC QLQ-C30, EORTC QLQ-CR29, EQ-5D, and GOG Ntx4 questionnaires. After completion of study treatment, patients are followed periodically for up to 7 years. Peer Reviewed and Funded by Medical Research Council (MRC) |
|||
Study Type ICMJE | Interventional | |||
Study Phase ICMJE | Phase 3 | |||
Study Design ICMJE | Allocation: Randomized Intervention Model: Parallel Assignment Masking: None (Open Label) Primary Purpose: Treatment |
|||
Condition ICMJE | Colorectal Cancer | |||
Intervention ICMJE |
|
|||
Study Arms ICMJE |
|
|||
Publications * |
|
|||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
||||
Recruitment Information | ||||
Recruitment Status ICMJE | Completed | |||
Actual Enrollment ICMJE |
6088 | |||
Original Estimated Enrollment ICMJE |
9500 | |||
Study Completion Date ICMJE | Not Provided | |||
Actual Primary Completion Date | November 2017 (Final data collection date for primary outcome measure) | |||
Eligibility Criteria ICMJE | DISEASE CHARACTERISTICS:
PATIENT CHARACTERISTICS:
PRIOR CONCURRENT THERAPY:
|
|||
Sex/Gender ICMJE |
|
|||
Ages ICMJE | 18 Years to 120 Years (Adult, Older Adult) | |||
Accepts Healthy Volunteers ICMJE | No | |||
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | |||
Listed Location Countries ICMJE | United Kingdom | |||
Removed Location Countries | ||||
Administrative Information | ||||
NCT Number ICMJE | NCT00749450 | |||
Other Study ID Numbers ICMJE | CDR0000613042 CRUK-SCOT ISRCTN59757862 EudraCT 2007-003957-10 EU-20874 SCOT-2007-01 |
|||
Has Data Monitoring Committee | Yes | |||
U.S. FDA-regulated Product | Not Provided | |||
IPD Sharing Statement ICMJE | Not Provided | |||
Current Responsible Party | Laura Alexander, Cancer Research UK, Glasgow | |||
Original Responsible Party | Not Provided | |||
Current Study Sponsor ICMJE | Cancer Research UK, Glasgow | |||
Original Study Sponsor ICMJE | NHS Greater Glasgow and Clyde | |||
Collaborators ICMJE | Not Provided | |||
Investigators ICMJE |
|
|||
PRS Account | Cancer Research UK, Glasgow | |||
Verification Date | July 2018 | |||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |